Search

Your search keyword '"Habermann, Thomas M."' showing total 97 results

Search Constraints

Start Over You searched for: Author "Habermann, Thomas M." Remove constraint Author: "Habermann, Thomas M." Database Journals@OVID Remove constraint Database: Journals@OVID
97 results on '"Habermann, Thomas M."'

Search Results

1. High-Dose Methotrexate in Patients With Lymphoma: Predictors of a Complicated Course

3. MYD88 mutation status does not impact overall survival in Waldenström macroglobulinemia

4. A susceptibility locus for classical Hodgkin lymphoma at 8q24 near MYC/PVT1 predicts patient outcome in two independent cohorts

5. Cohort Profile: The Lymphoma Specialized Program of Research Excellence (SPORE) Molecular Epidemiology Resource (MER) Cohort Study

6. Rituximab extended schedule or retreatment trial for low tumour burden non-follicular indolent B-cell non-Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402

7. Analysis of Heritability and Shared Heritability Based on Genome-Wide Association Studies for 13 Cancer Types

9. Dexamethasone, rituximab and cyclophosphamide for relapsed and/or refractory and treatment‐naïve patients with Waldenstrom macroglobulinemia

12. Diagnosis and Management of Waldenström Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines 2016

13. Personalized risk prediction for event-free survival at 24 months in patients with diffuse large B-cell lymphoma

14. Evaluation of the International Prognostic Score (IPS-7) and a Simpler Prognostic Score (IPS-3) for advanced Hodgkin lymphoma in the modern era

18. Elevated monoclonal and polyclonal serum immunoglobulin free light chain as prognostic factors in B- and T-cell non-Hodgkin lymphoma

21. Genetic polymorphisms in oxidative stress-related genes are associated with outcomes following treatment for aggressive B-cell non-Hodgkin lymphoma

25. Cytokine gene polymorphisms and progression-free survival in classical Hodgkin lymphoma by EBV status: Results from two independent cohorts

28. A phase I trial of immunostimulatory CpG 7909 oligodeoxynucleotide and 90yttrium ibritumomab tiuxetan radioimmunotherapy for relapsed B-cell non-Hodgkin lymphoma

42. Diagnosis and Management of Waldenström Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines

Catalog

Books, media, physical & digital resources